Literature DB >> 17322146

Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate.

Mona Darwish1, Mary Kirby, Philmore Robertson, William Tracewell, John G Jiang.   

Abstract

This study assessed the absolute and relative bioavailabilities and transmucosal and gastrointestinal absorbency of fentanyl buccal tablet (FBT) and oral transmucosal fentanyl citrate (OTFC). In a randomized crossover design, 26 healthy subjects received FBT 400 microg (transmucosal), FBT 800 microg (oral), OTFC 800 microg (transmucosal), and fentanyl 400 microg (intravenous). The transmucosal FBT had the highest absolute bioavailability (0.65) compared with the oral FBT (0.31) or transmucosal OTFC (0.47). More fentanyl was absorbed transmucosally from FBT than OTFC (48% vs 22%). Median t(max) values were shorter following the transmucosal FBT (47 minutes) than the oral FBT (90 minutes) or the transmucosal OTFC (91 minutes). Transmucosal administration of FBT compared with dose-normalized OTFC resulted in higher total systemic fentanyl exposure, higher early systemic exposure, and higher C(max). The rate and extent of fentanyl absorption were greater following administration of FBT compared to OTFC. An approximately 30% smaller dose of FBT achieved systemic exposures comparable to OTFC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322146     DOI: 10.1177/0091270006297749

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  25 in total

1.  Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study.

Authors:  Mona Darwish; Mary Kirby; Philmore Robertson; William Tracewell; Fang Xie
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Susan Frisbee-Hume; Minjeong Park; Diane Liu; Diwakar D Balachandran; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2017-08-10       Impact factor: 3.612

Review 3.  Fentanyl Formulations in the Management of Pain: An Update.

Authors:  Stephan A Schug; Sonya Ting
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

4.  Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy.

Authors:  Mona Darwish; Ehab Hamed; John Messina
Journal:  Perspect Medicin Chem       Date:  2010-06-04

5.  Single-dose pharmacokinetics of fentanyl buccal soluble film.

Authors:  Niraj Vasisht; Larry N Gever; Ignacio Tagarro; Andrew L Finn
Journal:  Pain Med       Date:  2010-05-18       Impact factor: 3.750

Review 6.  Fentanyl for the treatment of tumor-related breakthrough pain.

Authors:  Helmar Bornemann-Cimenti; Mischa Wejbora; Istvan S Szilagyi; Andreas Sandner-Kiesling
Journal:  Dtsch Arztebl Int       Date:  2013-04-19       Impact factor: 5.594

7.  Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.

Authors:  Niraj Vasisht; Larry N Gever; Ignacio Tagarro; Andrew L Finn
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

8.  Canadian recommendations for the management of breakthrough cancer pain.

Authors:  P Daeninck; B Gagnon; R Gallagher; J D Henderson; Y Shir; C Zimmermann; B Lapointe
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

9.  Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers.

Authors:  Mona Darwish; Kenneth Tempero; John G Jiang; Philip G Simonson
Journal:  Arch Drug Inf       Date:  2008-09

10.  Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers.

Authors:  Mona Darwish; Kenneth Tempero; John G Jiang; Philip G Simonson
Journal:  Arch Drug Inf       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.